31 results about "Cardiometabolic disease" patented technology

Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed.

The present disclosure relates to methods of treating or preventing metabolic syndrome and / or cardiometabolic disease by administration of 15-HEPE, 15-HETrE, or compositions thereof.

The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.

Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and related medical uses are also described.

The present disclosure relates to a method for measuring aggregation of low-density lipoprotein (LDL). The susceptibility of LDL to aggregate is an important factor regarding prognosis, diagnosis and surveillance of atherosclerotic cardiovascular diseases and cardiometabolic diseases, such as type 2 diabetes and related conditions, at various stages of their development. Also provided are methods of treatment of such diseases in subjects in need thereof.

The present invention relates to methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases. The inventors identified osteopontin (OPN) as a critical mediator of adipose tissue remodeling and senescence in obesity and extends this observation to related co-morbidities such as cardiomyopathy. Said result raises the possibility that inhibition of OPN activity may be of value in the prevention of cardiometabolic disease, in particular metabolic cardiomyopathy for which no specific treatment is yet available. In particular, the present invention relates to a method of treating an age-related cardiometabolic disease in an elderly subject in need thereof comprising administering to the subject a therapeutically effective amount of an osteopontin (OPN) inhibitor.

The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

Provided herein are methods, compounds, and compositions for reducing expression of an AGPAT5 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids, insulin resistance and / or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cardiometabolic disease, disorder or condition, or a physiological marker thereof, in an individual in need.

Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions

A method comprising: receiving, for each of a plurality of subjects, each having a specified type of cardiovascular or cardiometabolic disease and receiving at least one specified therapy from a set of therapies for treating cardiovascular and cardiometabolic diseases, a first score representing a first genetic predisposition in said subject to respond to one or more of said set of therapies; at a training stage, training a machine learning model on a training set comprising: (i) all of said first scores, and labels associated with a response in each of said subjects to said at least one specified therapy; and at an inference stage, apply said trained machine learning model to a target said first score received with respect to a target subject, to predict a response in said target subject to at least one of said therapies in said set.